Vir Biotechnology, Inc. (VIR)

Environment story

Vir Biotechnology discloses no Scope 1, Scope 2, or Scope 3 emissions data, net-zero targets, or sustainability initiatives in its 10-K filing. The company does not publicly report environmental metrics, carbon footprint, renewable energy usage, or climate commitments. No environmental controversies, fines, or resource-consumption disputes are documented in available sources. As a clinical-stage biopharmaceutical company focused on R&D and manufacturing of therapeutic products (monoclonal antibodies, masked TCEs, siRNA), environmental impact is likely moderate but unquantified. Absence of disclosed environmental strategy and metrics results in a conservative baseline score with deductions for lack of transparency on Scope 3 emissions (product manufacturing and clinical trial operations) and undisclosed net-zero commitments.

Social story

Vir Biotechnology reports 367 employees as of December 31, 2025, with 282 engaged in R&D. The company states 'none of our employees are represented by a labor union' and considers employee relations 'good.' No documented union-suppression activities, strikes, or NLRB complaints are evident. The company offers competitive compensation including base pay, cash bonuses, equity incentives, 401(k) matching, comprehensive health insurance, paid parental leave, and an employee stock purchase plan. Vir proactively addresses pay equity through independent third-party audits and supports employee resource groups, heritage events, inclusive mentoring, and developmental training. However, specific CEO-to-median-worker pay ratio, executive/board gender diversity percentages, and detailed turnover rate are not disclosed in the 10-K. Supply-chain ethics regarding manufacturing partners and clinical trial vendors are not explicitly detailed. Positive indicators include formalized equity and inclusion initiatives and no documented labor controversies within 24 months.

Governance story

Vir Biotechnology was incorporated as a Delaware corporation in April 2016. The 10-K filing does not explicitly disclose board independence percentage, dual-class share structure details, or annual lobbying expenditures. No active antitrust proceedings, consumer-safety regulatory actions, or financial-fraud investigations are documented in the filing. The company discloses no SEC consent decrees, material fines, or significant regulatory penalties. Governance risks highlighted in the 10-K relate to regulatory uncertainty (FDA policy changes, healthcare reform, drug pricing pressures from Inflation Reduction Act) rather than internal governance failures. The company has a sales agreement with Cowen and Company LLC for up to $300 million in equity issuance (as of December 31, 2025, no shares issued). No evidence of shareholder litigation, activist challenges, or governance disputes is documented. Absence of disclosed board independence metrics and lobbying spend prevents full evaluation; conservative scoring applied due to incomplete governance transparency.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Vir Biotechnology, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Vir Biotechnology, Inc. in the app for interactive charts and portfolio building.

More in Healthcare